Precision Peptide Company moves thymosin alpha-1 patch into US testing
The transdermal delivery route would avoid injection for an immune peptide now used mainly in compounded and overseas formulations.
PR
By Priya Raman · Science Reporter
Sep 8 08:30 ETSource: kalkine.ca
The wire
- 01The Precision Peptide Company says it has advanced a thymosin alpha-1 transdermal patch into formal testing in the United States.
- 02Thymosin alpha-1 is widely used in compounded immune protocols, so a controlled, non-injectable formulation would change how prescribers source and dose it.
- 03Details of the study design, endpoints and timelines are not disclosed in the report, and the claim comes from the company.
From the source
Read at kalkine.caThe Precision Peptide Company Advances Thymosin Alpha-1 Transdermal Patch Into Formal U.S. Testing